Gastrointestinal Cancer Global Market Report 2025

The gastrointestinal cancer market size has grown rapidly in recent years. It will grow from $24.09 billion in 2024 to $27.05 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The expansion during the historic period was fueled by the increasing incidence of GI cancers, heightened tobacco and alcohol use, a rising elderly population, unhealthy dietary patterns, and significant progress in cancer diagnostics and treatment methods.

The gastrointestinal cancer market size is expected to see rapid growth in the next few years. It will grow to $42.45 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. This anticipated growth is driven by the wider application of biomarker-based therapies, greater public awareness regarding early cancer detection, strengthened healthcare systems, supportive government programs for oncology care, and a rising preference for less invasive treatment techniques. Key market trends projected for this period include advancements in diagnostic technologies, breakthroughs in targeted and immunotherapies, integration of artificial intelligence in cancer management, and continued progress in precision medicine research.

The rising adoption of targeted therapies is expected to propel the growth of the gastrointestinal cancer market going forward. Targeted therapies are treatments that precisely block cancer cell growth by acting on specific molecular targets, reducing harm to normal, healthy cells. These therapies are designed to act on specific molecular pathways or genetic mutations driving a disease, especially in cancer. Unlike traditional treatments like chemotherapy, which attack both healthy and diseased cells, targeted therapies focus on the unique characteristics of a patient's condition. In the case of gastrointestinal (GI) cancer, targeted therapies act on specific genes or proteins that control tumor growth, enabling precise and effective treatment. This approach results in better outcomes with fewer side effects compared to conventional chemotherapy. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, there were 247 gene therapies in Phase II by the end of quarter one (Q1) 2023, which rose by 5% to reach 260 by the end of quarter two (Q2). Therefore, the rising adoption of targeted therapies is driving the growth of the gastrointestinal cancer market.

Major companies operating in the gastrointestinal cancer market are focused on developing advanced solutions, such as monoclonal antibody treatment, to improve patient survival rates and minimize treatment-related side effects. Monoclonal antibody treatment involves using laboratory-produced antibodies that precisely identify and attach to cancer cells, assisting the immune system in targeting and eliminating them. For instance, in September 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, launched VYLOY (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy, which received approval from the European Commission. It is a first-line treatment for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express claudin 18.2 (CLDN18.2). This approval makes VYLOY the first and only therapy in the European Union targeting CLDN18.2, a biomarker present in about 38% of these patients, based on positive clinical trial data from the SPOTLIGHT and GLOW studies.

In February 2025, GSK plc, a UK-based pharmaceutical and biotechnology company, acquired IDRx Inc. for approximately $1.15 billion. With this acquisition, GSK aims to strengthen its immunology and infectious disease pipeline, accelerate the development of innovative therapies, and expand its capabilities in precision medicine to better address unmet medical needs. IDRx Inc. is a US-based clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST).

Major players in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Parexel International Corporation, Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, and Taiho Pharmaceutical Co. Ltd.

North America was the largest region in the gastrointestinal cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastrointestinal cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastrointestinal cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gastrointestinal (GI) cancer comprises a group of malignancies that affect the digestive organs, including the esophagus, stomach, liver, pancreas, gallbladder, small intestine, colon, and rectum. These cancers occur when abnormal cells begin to grow uncontrollably within the gastrointestinal tract. The primary objectives of GI cancer treatment are to remove or manage the cancer, alleviate associated symptoms, and enhance the patient’s quality of life.

The major categories of gastrointestinal cancer include colorectal cancer, stomach cancer, esophageal cancer, pancreatic cancer, liver cancer, and others. Colorectal cancer, which affects the colon or rectum, is largely influenced by genetic predispositions and lifestyle factors, making it suitable for focused screening and specialized treatment approaches in GI oncology. Diagnosis is conducted using techniques such as endoscopy, biopsy, molecular diagnostics, imaging, and more. Treatment options consist of chemotherapy, immunotherapy, targeted therapy, radiation therapy, surgery, and other modalities. These are utilized across various settings, including hospitals, oncology centers, diagnostic labs, research institutions, and others.

The gastrointestinal cancer market research report is one of a series of new reports that provides gastrointestinal cancer market statistics, including the gastrointestinal cancer industry global market size, regional shares, competitors with the gastrointestinal cancer market share, detailed gastrointestinal cancer market segments, market trends, opportunities, and any further data you may need to thrive in the gastrointestinal cancer industry. This gastrointestinal cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gastrointestinal cancer market consists of revenues earned by entities by providing services such as genetic counseling and testing, palliative and supportive care, nutrition and dietary support, rehabilitation services, and follow-up and survivorship programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastrointestinal cancer market includes sales of laparoscopic instruments, robotic surgery systems, pain management medications, and monitoring tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.